



PATENT

ATTORNEY DOCKET NO. 50218/0020

TECH CENTER 1630/2

42 JUL 2001

RECEIVED

Certificate of Mailing: Date of Deposit: July 9, 2001

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Julie A. Bowen

Printed name of person mailing correspondence

Signature of person mailing correspondence

*John H. Bowen*  
re of person mailing correspondence

5/3/24/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Fahri Saatcioglu

Art Unit: 1642

Serial No.: 09/743,682

Examiner: S. Rawlings

Filed: January 10, 2001

Customer No.: 21559

## DIFFERENTIALLY EXPRESSED GENES IN PROSTATE CANCER

Assistant Commissioner for Patents  
Washington, D.C. 20231

REPLY TO NOTICE TO COMPLY WITH REQUIREMENTS  
FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE AND/OR AMINO ACID SEQUENCES

In reply to the Notice To Comply mailed June 7, 2001, Applicant submits the following:

- ☒ A substitute paper copy of the sequence listing and an amendment directing its entry into the specification.
- ☒ An initial copy of the sequence listing in computer readable form.
- ☒ A statement that the contents of the paper and computer readable copies are the same and contain no new matter.


If there are any charges, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 9 July 2001



Kristina Bieker-Brady, Ph.D.  
Reg. No. 39,109

  
Reg. No. 43,580

21559

PATENT TRADEMARK OFFICE

\Clark-w2k1\documents\50218\50218.002003 Reply to Notice to Comply.wpd

Clark & Elbing LLP  
176 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045

Jul-03-01 12:01pm

From-HSPH Dept of Nu



+617 432 2435

T-068 P.002/004 F-144

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

CA

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/743,682 01/10/01 SAATCIOLGLU

F 586.02-US1

EXAMINER

024392  
FISH & ASSOCIATES, LLP  
1440 N. HARBOR BLVD.  
SUITE 706  
FULLERTON CA 92835

HM12/0607

RAWI TINGS, S

ART UNIT	PAPER NUMBER
----------	--------------

1642

4

DATE MAILED:

06/07/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

JUL 17 2001

TECH CENTER 1600/2900

RECEIVED



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
 UNITED STATES PATENT AND TRADEMARK OFFICE  
 WASHINGTON, DC 20231  
 www.uspto.gov

JUL 13 2001

APPLICATION NO./  
CONTROL NO.

FILING DATE

FIRST NAMED INVENTOR /  
PATENT IN REEXAMINATION

ATTORNEY DOCKET NO.

09/743 682

EXAMINER

ART UNIT PAPER

4

DATE MAILED:

TECH CENTER 1600/2905

JUL 17 2001

RECEIVED

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN 30 days FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stephen L. Rawls, Ph.D., whose telephone number is (703) 305-3008. The examiner can normally be reached on Monday-Thursday and alternate Fridays from 8:00 AM to 5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa, Ph.D. can be reached at (703) 305-3995. The fax number for the organization where this application or proceeding is assigned is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

DONNA WORTMAN  
PRIMARY EXAMINER

## Notice to Comply

JUL 13 2001

## Application No.

09/743,682

## Examiner

Stephen L. Rawlings, Ph.D.

## Applicant(s)

SAATCIOGLU, FAHRI

## Art Unit

1642

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other:

## Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance..... 703-287-0200

To Purchase PatentIn Software..... 703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

RECEIVED  
JUL 17 2001  
TECH CENTER 1600/2900